z-logo
open-access-imgOpen Access
Ghrelin attenuates imiquimod‐induced psoriasiform skin inflammation in mice
Author(s) -
Kaneda Kazuma,
Yu Akitoshi,
Tanizaki Hideaki,
Kurokawa Teruo,
Yamamoto Yuki,
Furukawa Fukumi,
Moriwaki Shinichi
Publication year - 2019
Publication title -
journal of cutaneous immunology and allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.127
H-Index - 1
ISSN - 2574-4593
DOI - 10.1002/cia2.12086
Subject(s) - ghrelin , psoriasis , medicine , inflammation , imiquimod , erythema , endocrinology , hormone , dermatology
Objectives The endogenous peptide ghrelin, which is produced in the stomach, plays a pivotal role in secretion of growth hormone, regulation of energy metabolism, and cardiovascular protection; however, its anti‐inflammatory action has recently gained immense attention, as this peptide is presumed to be effective in patients with heart failure and chronic lung diseases. In dermatology, psoriasis acts as a typical chronic intractable disease, which may be severe, and although biologic agents have been recommended and used for its treatment in recent years, their application is not clear. We administered ghrelin to IMQ‐induced psoriasis‐like mouse model and examined the anti‐inflammatory effect of ghrelin. Methods In the present study, we induced psoriasiform skin inflammation via the continuous application of imiquimod cream on the backs of BALB/c mice and examined the gross and histopathological effect of the subcutaneous administration of ghrelin on psoriasiform skin inflammation. Results It was confirmed that the administration of ghrelin improved various scores, including erythema, scales, and epidermal thickening scores, in mice with psoriasiform skin inflammation. Conclusions The results suggest that ghrelin may be effective in treating psoriasis, including cases involving intractable skin lesions that are resistant to conventional therapies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here